Brief: Hansoh Pharmaceutical Says HS-20,093 Meets Primary Endpoint In Phase III SCLC Trial
10/07/2026 16:13
BRIEF-Hansoh Pharmaceutical Says HS-20,093 Meets Primary Endpoint In Phase III SCLC Trial July 10 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK:
HS-20,093 MEETS PRIMARY ENDPOINT IN PHASE III SCLC TRIAL
Further company coverage: 3692.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion